UK NHS brings new IMRT data to prostate cancer policy
This article was originally published in Clinica
Executive Summary
A UK NHS-led health technology assessment (HTA) of intensity-modulated radiotherapy (IMRT) for localised prostate cancer has concluded that biochemical survival can be improved by increasing the dosage, but that questions hang over the cost-effectiveness of the procedure.